Biological determinants of neointimal proliferation after intracoronary therapy with drug-eluting devices: role of endothelial progenitor cells and cytokines

Endothelial progenitor cells and plaque burden in stented coronary artery segments: an optical coherence tomography study six months after elective PCI

“…EPC are seen as a surrogate biomarker of cardiovascular health and vascular functional status [ 7 ]. A decreased EPC pool has been linked to adverse cardiovascular events, in-stent neointimal hyperplasia and endothelial dysfunction [ 5 – 7 , 25 ]. Current evidence for the protective role of EPC mainly derives from animal and ex vivo studies, while most clinical studies rely on surrogate parameters for atherosclerotic disease severity [ 27 – 30 ].…”

“…EPC were identified by flow cytometry according to their surface antigens CD34, CD133 and KDR as described before [9, 25]. Red blood cells were lysed using lysing solution.…”

“…Peripheral venous blood samples were drawn a day prior PCI for assessment of EPC additional to routine blood work according to the hospital’s standard operating procedures. EPC were identified by flow cytometry according to their surface antigens CD34, CD133 and KDR as described before [ 9 , 25 ]. Red blood cells were lysed using lysing solution.…”

Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England

“…In England, significant costs are devoted to treating and managing potentially avoidable diabetes complications. The most comprehensive estimate of total annual cost of type 1 and type 2 diabetes to the National Health Service (NHS) was £9.8 billion in 2010/11; 1 inflating this cost gives an estimated direct cost for 2016/2017 of £11.5 billion. Avoiding short- and long-term complications requires frequent hemoglobin A1c (HbA1c) testing and daily self-monitoring of blood glucose (SMBG) for type 1 and insulin-treated type 2 diabetes patients.…”

“…Avoiding short- and long-term complications requires frequent hemoglobin A1c (HbA1c) testing and daily self-monitoring of blood glucose (SMBG) for type 1 and insulin-treated type 2 diabetes patients. 1 SMBG encompasses a system of strips paired with a device that tracks glucose concentrations multiple times per day for patients treated with intensive insulin therapy. Frequent SMBG improves HbA1c and assists in avoiding diabetes-related complications.…”